A MULTIFACETED DIGITAL HEALTH PLATFORM TO ADVANCE ALZHEIMER'S DISEASE PATIENT MONITORING, SAFETY, CARE, AND RESEARCH.

一个多层面的数字健康平台，可推进阿尔茨海默病患者的监测、安全、护理和研究。

• 批准号: 10325493
• 负责人: Jon Andrew Corkey
• 金额: $ 49.58万
• 依托单位: AMISSA, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325493
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Americas; Anxiety; Appointment; Architecture; Artificial Intelligence; Authorization documentation; Behavior; Behavioral; Biological Markers; Biometry; Caregiver Burden; Caregivers; Caring; Cellular Phone; Clinical Trials; Collection; Computer software; Dangerousness; Data; Data Collection; Databases; Decentralization; Dementia; Dementia caregivers; Detection; Devices; Disease; Disease Progression; Early Diagnosis; Elderly; Emergency Situation; Environment; Exhibits; Family; Feedback; Feeling; Fees; Frequencies; Future; Goals; Health; Health Insurance Portability and Accountability Act; Health behavior; Heart Rate; Home; Hour; Individual; Intervention; Intervention Studies; Interview; Knowledge; Life; Location; Longevity; Longitudinal trends; Measures; Medical Research; Mind; Minority Groups; Modeling; Monitor; Notification; Onset of illness; Outcome; Parents; Patient Care; Patient Monitoring; Patient Recruitments; Patient Self-Report; Patient Transfer; Patients; Pattern; Performance; Personal Computers; Personal Satisfaction; Persons; Phase; Phenotype; Physical Exercise; Physicians; Population; Population Heterogeneity; Preventive treatment; Process; Public Health; Quality of life; Research; Research Personnel; Research Support; Resources; Rural Population; S Phase; Safety; Sampling; Scientist; Secure; Shame; Small Business Innovation Research Grant; Stigmatization; Stress; Symptoms; Techniques; Technology; Testing; Time; Travel; United States National Institutes of Health; Universities; Visual; base; caregiving; clinically relevant; cloud based; community based evaluation; cost; dashboard; data exchange; design; digital; digital health; experience; falls; handheld mobile device; humiliation; improved; insight; lifestyle intervention; loved ones; meetings; mobile application; modifiable behavior; multimodal data; novel; patient safety; peace; prevent; prototype; racial minority; recruit; remote monitoring; remote patient monitoring; rural underserved; sedentary lifestyle; sensor; sleep behavior; smart watch; social; social stigma; socialization behavior; tool; volunteer

Project Summary Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) are projected to affect 50 million Americans by 2050. In 2019, more than 16 million Americans struggled while providing unpaid care for people with AD/ADRD and they need stigma-free solutions to help remotely monitor challenging AD/ADRD behaviors like falling and wandering. Separate but related, many AD/ADRD clinical trials are siloed and require patient volunteers and their caregivers to travel to in-person appointments. This is burdensome for families, increases the cost to conduct studies, and data collected is often non-representative of daily life. Amissa Inc. has developed a stigma- free, prototype solution to significantly advance AD/ADRD patient monitoring, safety, and caregiving while simultaneously aggregating high-frequency digital biomarkers to advance medical research. Several competitors have developed hardware devices for tracking elderly individuals who wander and/or fall however, AD/ADRD patients express feelings of stress, anxiety, humiliation, burden, and stigma associated with dementia when wearing these “special” devices. AD/ADRD caregivers seek “socially-acceptable” devices that improve health and location monitoring, provide peace of mind, reduce worry, improve patient safety and quality of life without loved ones feeling shame or embarrassment. Amissa’s prototype software application, created for widely available, consumer-grade smartwatches, enables families to remotely monitor when loved ones fall inside or outside the home and help prevent dangerous wandering episodes. Our initial software application also sends emergency push notifications to key stakeholders when loved ones exhibit uncommon behaviors (e.g. sudden change in variable heart rate). This Phase I SBIR proposal is designed to develop a platform which passively and unobtrusively collects time-based behavioral and biometric data from AD/ADRD patient smartwatches in real-life settings to improve caregiving while also establishing a high-frequency cloud database where one does not currently exist for AD/ADRD research. Aim 1 will develop a caregiver-designed AD/ADRD patient monitoring application for off-the-shelf consumer smartwatches and conduct user-experience and user-interface testing to facilitate feedback for iterative product design improvement. Utilizing opt-in user data from Amissa’s caregiver monitoring application, Aim 2 will establish a novel high-frequency behavioral and biometric cloud database to advance AD/ADRD digital biomarker research capabilities to predict patient falls an wandering. Amissa’s project intends to enable faster collection of multimodal data via broader demographic populations to advance AD/ADRD medical research. This Phase I SBIR has the potential for high impact by providing a single, low-cost, digital technology solution to improve AD/ADRD patient care and safety while reducing stress for caregivers and families. Furthermore, this research will improve capabilities and reduce costs of conducting decentralized clinical trials in real-life environments. At scale, our goal is to advance the forecasting of symptom trajectories and enable physicians to suggest personalized preventative treatments to delay onset or prevent AD/ADRD.

项目摘要 阿尔茨海默氏病（AD）和与广告相关的痴呆症（ADRD）预计将影响5000万美国人 2050年。2019年，超过1600万美国人在为AD/ADRD的人提供无薪护理时挣扎 他们需要无污名的解决方案，以帮助远程监控挑战广告/ADRD行为，例如跌倒和 流浪。单独但相关，许多AD/ADRD临床试验都是孤立的，需要患者志愿者和 他们的护理人员去面对面的约会。对于家庭来说，这很繁重，增加了 进行研究，收集的数据通常不是日常生活的代表性。 Amissa Inc.已建立了污名化 - 免费的原型解决方案，可显着提高AD/ADRD患者监测，安全性和护理 同时汇总高频数字生物标志物以推进医学研究。几个竞争对手 已经开发了用于跟踪老年人徘徊和/或跌倒的硬件设备，但是AD/ADRD 患者表达与痴呆有关 戴上这些“特殊”设备。广告/ADRD护理人员寻求“社交可接受的”设备，以改善健康状况 和位置监控，提供安心，减轻忧虑，改善患者的安全和生活质量，没有 亲人感到震惊或尴尬。 Amissa的原型软件应用程序，为广泛创建 可用的消费级智能手表，使家庭能够远程监视亲人何时掉入室内或 在家外面，有助于防止危险的流浪情节。我们的初始软件应用程序也发送 当亲人表现出罕见的行为时，关键利益相关者的紧急提示通知（例如 可变心率的变化）。该阶段I SBIR提案旨在开发一个平台，可被动地 并毫不显眼地从AD/ADRD患者智能手表中收集基于时间的行为和生物识别数据 现实生活中的设置以改善护理，同时还建立了一个高频云数据库 目前不存在广告/ADRD研究。 AIM 1将开发护理人员设计的广告/ADRD患者监测 用于现成的消费者智能手表的应用程序，并进行用户体验和用户界面测试 促进迭代产品设计改进的反馈。利用Amissa护理人员的选择加入用户数据 监视应用程序，AIM 2将建立一个新颖的高频行为和生物特征界数据库 提前的广告/ADRD数字生物标志物研究能力可以预测患者流浪。 Amissa的项目 打算通过更广泛的人口统计种群来更快地收集多模式数据，以推进广告/ADRD 医学研究。这阶段I SBIR通过提供单个，低成本的数字，具有高影响力 改善AD/ADRD患者护理和安全性的技术解决方案，同时减轻护理人员的压力和 家庭。此外，这项研究将提高能力并降低进行分散的成本 现实生活环境中的临床试验。从大致上，我们的目标是推进症状轨迹的预测 并使医生能够建议个性化的预防性治疗，以延迟发作或预防AD/ADRD。